100 related articles for article (PubMed ID: 25483711)
21. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
22. Role of thioredoxin 1 and thioredoxin 2 on proliferation of human adipose tissue-derived mesenchymal stem cells.
Song JS; Cho HH; Lee BJ; Bae YC; Jung JS
Stem Cells Dev; 2011 Sep; 20(9):1529-37. PubMed ID: 21158569
[TBL] [Abstract][Full Text] [Related]
23. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
24. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells.
Li X; Rong Y; Zhang M; Wang XL; LeMaire SA; Coselli JS; Zhang Y; Shen YH
Biochem Biophys Res Commun; 2009 Apr; 381(4):660-5. PubMed ID: 19254690
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
[TBL] [Abstract][Full Text] [Related]
27. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
28. FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.
Sewastianik T; Szydlowski M; Jablonska E; Bialopiotrowicz E; Kiliszek P; Gorniak P; Polak A; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Kaminski TS; Markowicz S; Nowak E; Grygorowicz MA; Warzocha K; Juszczynski P
Oncogene; 2016 Nov; 35(46):5989-6000. PubMed ID: 27132507
[TBL] [Abstract][Full Text] [Related]
29. β-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells.
Fu Q; Chen Z; Gong X; Cai Y; Chen Y; Ma X; Zhu R; Jin J
Biochem Biophys Res Commun; 2015 May; 461(1):21-7. PubMed ID: 25849888
[TBL] [Abstract][Full Text] [Related]
30. Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1.
Han S; Wei W
Curr Eye Res; 2011 Jan; 36(1):71-7. PubMed ID: 21174601
[TBL] [Abstract][Full Text] [Related]
31. Altered thioredoxin subcellular localization and redox status in MCF-7 cells following 1,25-dihydroxyvitamin D3 treatment.
Byrne BM; Welsh J
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):57-64. PubMed ID: 16061374
[TBL] [Abstract][Full Text] [Related]
32. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines.
Di Michele M; Della Corte A; Cicchillitti L; Del Boccio P; Urbani A; Ferlini C; Scambia G; Donati MB; Rotilio D
Biochim Biophys Acta; 2009 Feb; 1794(2):225-36. PubMed ID: 18973835
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines.
Cao L; Li X; Zhang Y; Peng F; Yi H; Xu Y; Li X; Wang Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):286-94. PubMed ID: 20448348
[TBL] [Abstract][Full Text] [Related]
34. Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells.
Xia X; Ji T; Liu R; Weng Y; Fang Y; Wang Z; Xu H
Eur J Gynaecol Oncol; 2015; 36(6):662-6. PubMed ID: 26775347
[TBL] [Abstract][Full Text] [Related]
35. PCAF represses transactivation function of FOXO1 in an acetyltransferase-independent manner.
Yoshimochi K; Daitoku H; Fukamizu A
J Recept Signal Transduct Res; 2010 Feb; 30(1):43-9. PubMed ID: 20041807
[TBL] [Abstract][Full Text] [Related]
36. Expression of PUMA in Follicular Granulosa Cells Regulated by FoxO1 Activation During Oxidative Stress.
Liu ZQ; Shen M; Wu WJ; Li BJ; Weng QN; Li M; Liu HL
Reprod Sci; 2015 Jun; 22(6):696-705. PubMed ID: 25425107
[TBL] [Abstract][Full Text] [Related]
37. Post-transcriptional repression of FOXO1 by QKI results in low levels of FOXO1 expression in breast cancer cells.
Yu F; Jin L; Yang G; Ji L; Wang F; Lu Z
Oncol Rep; 2014 Mar; 31(3):1459-65. PubMed ID: 24398626
[TBL] [Abstract][Full Text] [Related]
38. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
39. Elevated expression of forkhead box protein O1 (FoxO1) in alcohol-induced intestinal barrier dysfunction.
Wang Y; Tong J; Zou D; Chang B; Wang B; Wang B
Acta Histochem; 2013 Jul; 115(6):557-63. PubMed ID: 23347700
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
